首页 | 本学科首页   官方微博 | 高级检索  
   检索      


DPHL:A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery
Institution:Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Westlake University, Hangzhou 310024, China;Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China;School of Computer Science, Shanghai Key Laboratory of Intellige;Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Westlake University, Hangzhou 310024, China;Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China;Thermo Fisher Scientific (BREMEN) GmbH, Bremen 28195, Germany;OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, VU University, Amsterdam 1011, The Netherlands;OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, VU University, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Urology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Thermo Fisher Scientific, Shanghai 201206, China;The Netherlands Cancer Institute, Surgical Oncology, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Surgery, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Hematology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Neurosurgery, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Erasmus MC University Medical Center, Pathology, Rotterdam 1016LV, The Netherlands;Erasmus MC University Medical Center, Surgery, Rotterdam 1016LV, The Netherlands;Erasmus MC University Medical Center, Medical Oncology, Rotterdam 1016LV, The Netherlands;Amsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Cancer Center Amsterdam, Amsterdam 1011, The Netherlands;Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608, Singapore;Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169608, Singapore;School of Computer Science and Engineering, Beihang University, Beijing 100191, China;MOE Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Translational Research, Peking University Cancer Hospital, Beijing 100142, China;Cancer Institute (MOE Key Laboratory of Cancer Prevention and Intervention, Zhejiang Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China;Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;Center for Stem Cell Research and Application, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China;Phase I Clinical Research Center, Zhejiang Provincial People's Hospital, Hangzhou 310014, China;Department of Laboratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China;College of Mathematics and Informatics, Digital Fujian Institute of Big Data Security Technology, Fujian Normal University, Fuzhou 350108, China;Zhejiang Provincial Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou 310015, China;Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Westlake University, Hangzhou 310024, China;Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou 310024, China;Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China;School of Computer Science, Shanghai Key Laboratory of Intelligent Information Processing, Fudan University, Shanghai 200433, China;Department of Biology, Institute for Molecular Systems Biology, ETH Zurich, Zurich 8092, Switzerland;Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong Special Administrative Region, China;Department of Biology, Institute for Molecular Systems Biology, ETH Zurich, Zurich 8092, Switzerland;Faculty of Science, University of Zurich, Zurich 8092, Switzerland
Abstract:To address the increasing need for detecting and validating protein biomarkers in clinical specimens, mass spectrometry (MS)-based targeted proteomic techniques, including the selected reaction monitoring (SRM), parallel reaction monitoring (PRM), and massively parallel data-independent acquisition (DIA), have been developed. For optimal performance, they require the fragment ion spectra of targeted peptides as prior knowledge. In this report, we describe a MS pipeline and spectral resource to support targeted proteomics studies for human tissue samples. To build the spectral resource, we integrated common open-source MS computational tools to assemble a freely accessible computational workflow based on Docker. We then applied the workflow to generate DPHL, a comprehensive DIA pan-human library, from 1096 data-dependent acquisition (DDA) MS raw files for 16 types of cancer samples. This extensive spectral resource was then applied to a proteomic study of 17 prostate cancer (PCa) patients. Thereafter, PRM validation was applied to a larger study of 57 PCa patients and the differential expression of three proteins in prostate tumor was validated. As a second application, the DPHL spectral resource was applied to a study consisting of plasma samples from 19 diffuse large B cell lymphoma (DLBCL) patients and 18 healthy control subjects. Differentially expressed proteins between DLBCL patients and healthy control subjects were detected by DIA-MS and confirmed by PRM. These data demonstrate that the DPHL supports DIA and PRM MS pipelines for robust protein biomarker discovery. DPHL is freely accessible at https://www.iprox.org/page/project.html?id=IPX0001400000.
Keywords:Data-independent acquisition  Parallel reaction monitoring  Spectral library  Prostate cancer  Diffuse large B cell lymphoma
本文献已被 万方数据 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号